Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome and type 2 diabetes

Chinese Medical Journal

Volumn 120, Issue 21, 2007, Pages 1918-1924

  Rizvi, Ali A ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Endothelial dysfunction; Inflammatory markers; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; INSULIN; INTERLEUKIN 6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STRESS; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 36248957135     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200711010-00014     Document Type: Article

References (68)

1. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33: 351-375.
2. Chan JC, Cheung JC, Stehouwer CD, Emeis JJ, Tong PC, Ko GT, et al. The central roles of obesity-associaied dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome - an analysis by structural equation modelling. Int J Obes Relat Metab Disord 2002; 26: 994-1008.
3. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 2003; 134: 10-17.
4. Reaven GM. Insulin resistance, cardiovascular disease, and the metabotic syndrome: how well do the emperor's clothes fit? Diabetes Care 2004; 27: 1011-1012.
5. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278-301.
6. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610-612.
7. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823.
8. Hansson JK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
9. Black PH. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003; 17: 350-364.
10. Shinozaki K, Kashiwagi A, Masada M, Okamura T. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4: 1 -11.
11. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. Obes Res 1998; 6 Suppl 2: 51S-209S.
12. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003: 92: 10J- 17J.
13. Ridker, PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
14. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
15. Stehouwer CD, Gall M, Twisk JW, Knudsen E, Emeis JJ, Parving H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165.
16. Duncan BB, Schmidt MI, Pankow JI, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes. The atherosclerosis risk in communities study. Diabetes 2003;. 52: 1799-1805.
17. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al.'C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-4600.
18. Asakawa H, Tokunaga. Y, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes patients with retinopathy and nephropathy. J Diabetes Complications 2000; 14: 121-126.
19. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetalogia 2003; 46: 1402-1407.
20. Tall AR. C-reative protein reassessed. N Engl J Med 2004; 350: 1450-1452.
21. Mosca L. C-reactive protein - to screen or not to screen? N Engl J Med 2002; 347: 1615-l6l7.
22. Hackam DG, Anand SS. Emerging risk factors for atheroclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290: 932-940.
23. Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 120-127.
24. Bhatt DL, Topol EJ. Need to test the inflammation hypothesis. Circulation 2002; 106: 136-140.
25. Cariello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823.
26. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, et.al. Differentiation between obesity and insulin resistance in the association with C-reactive, protein. Circulation 2002; 106: 2908-2912.
27. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
28. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
29. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
30. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2003; 23: 650-655.
31. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
32. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHANES III), National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
33. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002; 106: 2908-2912.
34. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
35. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.
36. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-385.
37. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004; 110: 803-809.
38. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
39. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600.
40. Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 3327-3334.
41. Takebayashi K, Suetsugu M, Matsutomo R, Wakabayashi S, Aso Y, Inukai T. Correlation of high-sensitivity C-reactive protein and plasma fibrinogen with individual complications in patients with type 2 diabetes. South Med J 2006; 99: 23-27.
42. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450.
43. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175.
44. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
45. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764-2769.
46. Kojima S, Funahashi T, Sakamoto T, Miyamoto S, Soejima H, Hokamaki J, et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003; 89: 667-672.
47. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al, Osaka CAD Study Group. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
48. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with-high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 25: 971-976.
49. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Motab 2000; 85: 3338-3342.
50. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414-417.
51. Fasshauer M,Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-1603.
52. Hotamisligil GS. Adipose expression of tumor necrosis factor: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
53. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995: 95: 2111-2119.
54. Unger RH. Longevity, lipotoxicity, and leptin: the adipocyte defense against feasting and famine. Biochimie 2005; 87: 57-64.
55. Franks PW, Brage S, Luan J, Ekelund U, Rahman M, Farooqi IS, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005 13:1476-1484.
56. Ridker PM, Rifai N, Pfeifer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-844.
57. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, el al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579: 295-301.
58. Ridker PM, Rifai N, Pfeifer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infraction in patients with average cholesterol levels. Circulation 1998; 98: 839-844.
59. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 18: 956-963.
60. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome: a population-based study. Diabetes Care 1998; 21: 649-654.
61. Schram MT, Stehouver CD. Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome. Horm Metab Res 2005; 37 Suppl 1: 49-55.
62. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders; AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945-949.
63. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
64. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willibrand factor with age, race, sex, and risk factors for atherosclerosis: the atherosclerosis risk in communities (ARIC) study. Thromb Haemost 1993; 70: 380-385.
65. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998; 22: 312-117.
66. Sakkinen PA, Wahl P, Cushman M, Lweis MR, Tracy RP. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
67. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Macchia G, et al. Hyperfibernogenemia and metabolic syndrome in type 2 diabetes: a poputation-based study. Diabetes Metab Res Rev 2001; 17: 124-130.
68. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.